LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer

Activating mutations in the KRAS and BRAF genes, leading to hyperactivation of the RAS/RAF/MAPK oncogenic signaling cascade, are common in patients with colorectal cancer (CRC). While selective BRAF inhibitors are efficacious in BRAF(mut) melanoma, they have limited efficacy in BRAF(mut) CRC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Vakana, Eliza, Pratt, Susan, Blosser, Wayne, Dowless, Michele, Simpson, Nicholas, Yuan, Xiu-Juan, Jaken, Susan, Manro, Jason, Stephens, Jennifer, Zhang, Youyan, Huber, Lysiane, Peng, Sheng-Bin, Stancato, Louis F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354729/
https://www.ncbi.nlm.nih.gov/pubmed/27999210
http://dx.doi.org/10.18632/oncotarget.14002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354729/
https://www.ncbi.nlm.nih.gov/pubmed/27999210
http://dx.doi.org/10.18632/oncotarget.14002

Ejemplares similares